Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Advanced Ovarian Cancer: A 2-year Survival Analysis Study
- 1 July 2024
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Women s Health Reviews
- Vol. 20 (4) , 1
Abstract
Background: During the last few years, Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has entered the national comprehensive cancer network guidelines as a new protocol for improving patients’ outcomes. However, there is no consensus on its long-term efficiency, and it still is under debate. Objectives: This study aims to evaluate the effectiveness of Cytoreductive Surgery Plus hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer in Iran. Method: Thirty patients with Stage IIIc and IV advanced ovarian cancer underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy at Jam Hospital with a fixed surgical team in Tehran, Iran, from 2019 to 2021. Fourteen patients were new cases, and sixteen of them were recurrent cases. At the end of cytoreductive surgery, by using a hyperthermic intraperitoneal chemotherapy device, Cisplatin was circulated in the peritoneal cavity for 90 minutes at a dose of 80-100 mg/ m2 at 43°C. Results: Among 30 patients with 54.97±10.74 years of mean age, the mean overall survival was 564.967 days, and 2-year survival rates were 66.7%. According to Fisher's exact test, there was a statistically significant relationship between disease-free after surgery and mortality rate (p=0.00). However, there was no statistically significant relationship between recurrence after surgery and mortality rate (p=0.093). Conclusion: Based on these findings, cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy had a survival rate of 66.7% within two years in advanced ovarian cancer patients. However, to achieve better results, careful selection of patients and complete cytoreductive surgery should be performed.Keywords
Funding Information
- Preventative Gynecology Research Center (31534)
This publication has 34 references indexed in Scilit:
- Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United StatesGynecologic Oncology, 2020
- Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?JAMA Network Open, 2020
- A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinomaEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2020
- Clinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy- largest single institute experienceEuropean Journal of Surgical Oncology, 2019
- Upfront debulking surgery versus interval debulking surgery for advanced tubo‐ovarian high‐grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPECJournal of Surgical Oncology, 2019
- Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysisEuropean Journal of Surgical Oncology, 2019
- Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trialsThe Lancet Oncology, 2018
- Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosisEuropean Journal of Surgical Oncology, 2018
- Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapyBritish Journal of Cancer, 2018
- Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: A systematic review of survival, mortality, and morbidityJournal of Surgical Oncology, 2011